LG Life Sciences-Green Cross Tie-up Might Not Trigger Matching Alliances By Other Korean Drug Makers
This article was originally published in PharmAsia News
Executive Summary
SEOUL - A recent deal covering cooperation in domestic and global sales between South Korea's second largest pharmaceutical company, Green Cross, and 10-ranked LG Life Sciences has not yet triggered any similar tie-ups by other major drug players
You may also be interested in...
Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions
SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company
Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions
SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company
Korea's LG Life Sciences Teams with Macrogen to Pool Genetics Databases for Personalized Medicines and Theranostics
SEOUL - South Korea's LG Life Sciences hopes to bring new life to its stalled oncology program by inking a memorandum of understanding with genomic services provider Macrogen to work together for the development and commercialization of personalized medicine using patients' genetic information